Nephrol Dial Transplant. 2010 Nov;25(11):3480-9. doi: 10.1093/ndt/gfq502. Epub 2010 Sep 8.
Several desensitization strategies have been investigated for the reversal of acute antibody-mediated rejection or for the removal of preformed anti-HLA antibodies, with the aim to promote access to renal transplantation. Today, their success appears limited or incomplete. Bortezomib, a selective inhibitor of the 26S proteasome, which is largely used in the treatment of multiple myeloma, could be a novel promising desensitizing agent. Its mechanism of action and preliminary clinical use in renal transplantation is reviewed here.
已经研究了几种脱敏策略来逆转急性抗体介导的排斥反应或去除预先形成的抗 HLA 抗体，目的是促进肾移植的开展。如今，它们的效果似乎有限或不完整。硼替佐米是 26S 蛋白酶体的选择性抑制剂，主要用于治疗多发性骨髓瘤，它可能是一种有前途的新型脱敏剂。本文回顾了其在肾移植中的作用机制和初步临床应用。
